Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes

Bobadilla, Javier Fernández de; Moreno, Ramón; Fernandez, Carla; Martinez, A.; Sánchez-Maestre, C; D, Ezpeleta-Echevarri

doi:10.33588/rn.4811.2009069

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The protective effect of statins on cardiovascular risk has been widely demonstrated previously in patients with previous heart disease 22–26 . However, the reproducibility of these results in patient with recent acute cerebrovascular disease was uncertain until the SPARCL study 7,27 .…”

Section: Discussionmentioning

confidence: 96%

“…7 The protective effect of statins on cardiovascular risk has been widely demonstrated previously in patients with previous heart disease. [22][23][24][25][26] However, the reproducibility of these results in patient with recent acute cerebrovascular disease was uncertain until the SPARCL study. 7,27 The Heart Protection Study evaluated the long-term effects of statin therapy on major vascular and non-vascular mortality and morbidity in patients at high risk of death from coronary heart disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease

Sicras‐Mainar¹,

Planas-Comes²,

Frias-Garrido³

et al. 2011

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease

Sicras‐Mainar¹,

Planas-Comes²,

Frias-Garrido³

et al. 2011

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Respecto a la intensidad de las estatinas, el ensayo TNT (Treating to New Targets) comparó atorvastatina 80 mg/día con atorvastatina 10 mg/día en pacientes con cardiopatía isquémica, observándose una reducción del 25% del riesgo relativo de ictus con atorvastatina 80 mg/día 46 . Estos datos se confirman en distintos metaanálisis que comparan estatinas de alta intensidad frente a otras, apreciándose con estatinas de alta intensidad reducciones del 14-18% en el riesgo relativo de ictus 32,47,48 y del 16% en los ictus isquémicos 32 .…”

Section: Estatinas En La Prevención Primaria Del Ictusunclassified

Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología

et al. 2022

View full text Add to dashboard Cite

The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review

Fang

Wang

et al. 2017

Intern Emerg Med

View full text Add to dashboard Cite

Inconsistent findings in the studies have been observed concerning the higher dose of statins use in the acute phase of ischemic stroke and transient ischemic attack (TIA). Therefore, we performed a systematic review to assess this issue. A computerized literature search in PubMed, Cochrane Library databases, and EMBASE for randomized controlled trials (RCTs) was conducted. The efficacy outcome indicators were National Institutes of Health Stroke Scale (NIHSS) score, infarct volume, and recurrence of stroke; the safety outcome indicators were intracranial hemorrhage events, cardiovascular and cerebrovascular events, and all-cause death. Pre-specified subgroup analyses were carried out. A total of seven RCTs with 1089 patients were included. Six studies reported the results of the NHISS score. A great reduction was found in NIHSS score in the statins group, and the difference is statistically significant [mean difference (MD) -1.15, 95% confidence interval (CI) -1.64 to -0.66, P < 0.00001]. However, no significant differences in the effect on recurrence of stroke [odds ratio (OR) 1.05, 95% CI 0.65-1.69, P = 0.85] (available in 3 studies), infarct volume [std. mean difference (SMD) 0.04, 95% CI -0.55 to 0.63, P = 0.89] (available in 2 studies), intracerebral hemorrhage events (OR 3.25, 95% CI 0.34-31.52, P = 0.31) (available in 2 studies), cardiovascular and cerebrovascular events (OR 0.70, 95% CI 0.35-1.43, P = 0.33) (available in 2 studies), and all-cause death (OR 1.18, 95% CI 0.60-2.35, P = 0.63) (available in 2 studies) were found. High-dose statin therapy in the acute phase of ischemic stroke and TIA significantly reduce the NIHSS score and improve short-term functional outcome without increasing related adverse events.

show abstract

Efecto del tratamiento intensivo con atorvastatina frente a dosis estándar de estatinas en el riesgo de ictus de pacientes con enfermedad coronaria previa. Metaanálisis de cinco ensayos aleatorizados con 25.709 pacientes

Cited by 5 publications

References 0 publications

Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease

Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease

Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología

The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review

Contact Info

Product

Resources

About